Brief: Anaptys To Announce Top-Line Data From Phase 2B Trial Of Rosnilimab, A PD-1 Depleter And Agonist, In Rheumatoid Arthritis
11/02/2025 22:47
Feb 11 (Reuters) - AnaptysBio Inc ANAB.O :
* ANAPTYS TO ANNOUNCE TOP-LINE DATA FROM PHASE 2B TRIAL OF
ROSNILIMAB, A PD-1 DEPLETER AND AGONIST, IN RHEUMATOID ARTHRITIS
ON FEB. 12, 2025
Source text: ID:nGNX2ssLQQ
Further company coverage: ANAB.O
Recent news on AnaptysBio
See all newsFirst Tracks Biotherapeutics up after $200 mln equity raise
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties